BG106151A - Pharmaceutical complex - Google Patents

Pharmaceutical complex

Info

Publication number
BG106151A
BG106151A BG106151A BG10615101A BG106151A BG 106151 A BG106151 A BG 106151A BG 106151 A BG106151 A BG 106151A BG 10615101 A BG10615101 A BG 10615101A BG 106151 A BG106151 A BG 106151A
Authority
BG
Bulgaria
Prior art keywords
complex
pharmaceutical complex
pharmaceutical
sulphobutylether
eletriptan
Prior art date
Application number
BG106151A
Other languages
Bulgarian (bg)
English (en)
Inventor
Anne Billotte
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of BG106151A publication Critical patent/BG106151A/xx

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG106151A 1999-06-29 2001-11-26 Pharmaceutical complex BG106151A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9915231.6A GB9915231D0 (en) 1999-06-29 1999-06-29 Pharmaceutical complex
PCT/IB2000/000746 WO2001000243A1 (en) 1999-06-29 2000-06-02 Pharmaceutical complex

Publications (1)

Publication Number Publication Date
BG106151A true BG106151A (en) 2002-05-31

Family

ID=10856302

Family Applications (1)

Application Number Title Priority Date Filing Date
BG106151A BG106151A (en) 1999-06-29 2001-11-26 Pharmaceutical complex

Country Status (44)

Country Link
US (2) US6713461B1 (cs)
EP (1) EP1189640B1 (cs)
JP (2) JP4454900B2 (cs)
KR (1) KR20020015067A (cs)
CN (1) CN1198654C (cs)
AP (1) AP2001002369A0 (cs)
AR (1) AR033337A1 (cs)
AT (1) ATE290884T1 (cs)
AU (1) AU770169B2 (cs)
BG (1) BG106151A (cs)
BR (1) BR0011845A (cs)
CA (1) CA2376847C (cs)
CO (1) CO5170494A1 (cs)
CZ (1) CZ20014572A3 (cs)
DE (1) DE60018744T2 (cs)
DZ (1) DZ3320A1 (cs)
EA (1) EA003908B1 (cs)
EC (1) ECSP003551A (cs)
EE (1) EE200100697A (cs)
ES (1) ES2235879T3 (cs)
GB (1) GB9915231D0 (cs)
GE (1) GEP20043377B (cs)
GT (1) GT200000102A (cs)
HR (1) HRP20010951A2 (cs)
HU (1) HUP0201629A3 (cs)
IL (1) IL146341A0 (cs)
IS (1) IS6163A (cs)
MA (1) MA26801A1 (cs)
MX (1) MXPA01013274A (cs)
NO (1) NO20016430L (cs)
NZ (1) NZ515235A (cs)
OA (1) OA11964A (cs)
PA (1) PA8496801A1 (cs)
PE (1) PE20010346A1 (cs)
PL (1) PL352902A1 (cs)
SK (1) SK18932001A3 (cs)
SV (1) SV2002000112A (cs)
TN (1) TNSN00142A1 (cs)
TR (1) TR200103827T2 (cs)
UA (1) UA66932C2 (cs)
UY (1) UY26224A1 (cs)
WO (1) WO2001000243A1 (cs)
YU (1) YU87501A (cs)
ZA (1) ZA200110454B (cs)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
CA2495864C (en) * 2002-08-20 2011-09-27 Bristol-Myers Squibb Company Aripiprazole complex formulation and method
GB0329918D0 (en) * 2003-12-24 2004-01-28 West Pharm Serv Drug Res Ltd Intranasal compositions
CN1296391C (zh) * 2004-03-04 2007-01-24 中国人民解放军第二军医大学 氟代羧烷基环糊精醚类化合物及其制备方法和应用
GB0613925D0 (en) 2006-07-13 2006-08-23 Unilever Plc Improvements relating to nanodispersions
CN101957330B (zh) * 2010-06-12 2013-10-09 南京巨环医药科技开发有限公司 磺丁基倍他环糊精含量的测定方法
WO2017122161A1 (en) * 2016-01-15 2017-07-20 Cadila Healthcare Limited An intranasal composition comprising 5ht1b/1d receptor agonists
US20190224171A1 (en) * 2018-01-22 2019-07-25 Insys Development Company, Inc. Liquid rizatriptan compositions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
HU211648A9 (en) 1990-03-28 1995-12-28 Chinoin Gyogyszer Es Vegyeszet Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same
HU210921B (en) 1990-03-28 1995-09-28 Chinoin Gyogyszer Es Vegyeszet Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them
WO1992006973A1 (en) 1990-10-15 1992-04-30 Pfizer Inc. Indole derivatives
CZ224995A3 (en) 1993-03-05 1995-12-13 Hexal Pharma Gmbh Crystalline cyclodextrin complexes of ranitidin hydrochloride, process of their preparation and pharmaceutical composition containing thereof
GB9417310D0 (en) 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
KR20000022239A (ko) 1996-07-11 2000-04-25 토마스 헤인 인돌 선택성 세로토닌 작용약을 함유한 내포 복합체
US5998462A (en) 1996-12-16 1999-12-07 Allelix Biopharmaceuticals Inc. 5-alkyl indole compounds
GB9704498D0 (en) 1997-03-05 1997-04-23 Glaxo Wellcome Spa Chemical compound
ID24528A (id) 1997-07-03 2000-07-20 Pfizer Komposisi-komposisi obat farmasi yang mengandung eletriptan hemisulfat dan kafein
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
GB9915231D0 (en) * 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex

Also Published As

Publication number Publication date
KR20020015067A (ko) 2002-02-27
US20040186076A1 (en) 2004-09-23
PA8496801A1 (es) 2002-02-21
CN1359303A (zh) 2002-07-17
EA200101106A1 (ru) 2002-06-27
SK18932001A3 (sk) 2002-09-10
GEP20043377B (en) 2004-04-13
MXPA01013274A (es) 2002-06-04
UY26224A1 (es) 2001-01-31
EE200100697A (et) 2003-02-17
JP4454900B2 (ja) 2010-04-21
TR200103827T2 (tr) 2002-05-21
CA2376847C (en) 2007-09-25
HRP20010951A2 (en) 2005-04-30
NO20016430D0 (no) 2001-12-28
NZ515235A (en) 2003-08-29
HUP0201629A2 (hu) 2003-03-28
CA2376847A1 (en) 2001-01-04
DE60018744T2 (de) 2006-05-18
EP1189640A1 (en) 2002-03-27
IS6163A (is) 2001-11-16
EP1189640B1 (en) 2005-03-16
BR0011845A (pt) 2002-03-05
DE60018744D1 (de) 2005-04-21
YU87501A (sh) 2004-05-12
DZ3320A1 (fr) 2001-01-04
PL352902A1 (en) 2003-09-22
ZA200110454B (en) 2002-12-20
JP2006257091A (ja) 2006-09-28
UA66932C2 (en) 2004-06-15
ECSP003551A (es) 2002-01-25
SV2002000112A (es) 2002-02-05
CN1198654C (zh) 2005-04-27
WO2001000243A1 (en) 2001-01-04
HUP0201629A3 (en) 2003-11-28
MA26801A1 (fr) 2004-12-20
GB9915231D0 (en) 1999-09-01
ATE290884T1 (de) 2005-04-15
CO5170494A1 (es) 2002-06-27
AP2001002369A0 (en) 2001-12-31
EA003908B1 (ru) 2003-10-30
TNSN00142A1 (fr) 2005-11-10
CZ20014572A3 (cs) 2002-08-14
NO20016430L (no) 2002-02-26
ES2235879T3 (es) 2005-07-16
AU4774100A (en) 2001-01-31
GT200000102A (es) 2001-12-14
US6713461B1 (en) 2004-03-30
OA11964A (en) 2006-04-17
JP2003503364A (ja) 2003-01-28
AU770169B2 (en) 2004-02-12
AR033337A1 (es) 2003-12-17
PE20010346A1 (es) 2001-03-26
IL146341A0 (en) 2002-07-25

Similar Documents

Publication Publication Date Title
MX9602683A (es) Compuestos de 6-dimetilaminometil-1-fenil-ciclohexano como substancias farmaceuticamente activas.
YU68199A (sh) Farmaceutske formulacije koje sadrže vorikonazol
NZ334124A (en) Use of the chelating agent clioquinol, with vitamin B12 for the manufacture of a pharmaceutical composition for the treatment of alzheimer's disease
HK1028594A1 (en) Adamantane derivatives
IL136369A0 (en) Adamantane derivatives
BG105459A (en) Pharmaceutical moxifloxacin preparation
HK1048986A1 (en) 2'-Substituted 1,1'-iphenyl-2-carbonamides, methodfor the production thereof, use thereof as medicament and pharmaceutical preparations containing said compounds.
ZA965752B (en) Triphenylethylenes, process for their production, pharmaceutical preparations that contain these triphenylethylenes as well as their use for the production of pharmaceutical agents.
HU229443B1 (en) Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
HK1024177A1 (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
MY118526A (en) Method for improving the pharmacokinetics of tipranavir
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
HUP9903353A3 (en) 7alpha-(methyl-amino-pentyl)-estratrienes, pharmaceutical preparations which contain said 7alpha-(5-methylaminopentyl) -estratrienes and use thereof for production of drugs
GEP20063719B (en) Prevention of Migraine Recurrence
BG104179A (en) Phanquinon administration for the treatment of the alzheimer's disease
BG106151A (en) Pharmaceutical complex
GB9907571D0 (en) Compounds
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
BG106534A (en) Oral solution containing galanthamine and a sweetening agent
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
ZA200300777B (en) Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts.
AP9901472A0 (en) Crystalline pharmaceutical product.
EP1234834A4 (en) 1,3,4-OXADIAZOLINE-2-ONE DERIVATIVES AND MEDICINAL PRODUCTS CONTAINING SUCH DERIVATIVES USEFUL AS ACTIVE INGREDIENT
UA41326C2 (uk) Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань
ZA200110073B (en) 14β-H-Sterols, pharmaceutical compositions comprising them and use of these derivatives for the preparation of meiosis regulating medicaments.